KC 764

Known as: KC-764 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-1994
024619921994

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
KC-764, developed as a cyclo-oxygenase inhibitor, was administered to gerbils in a dose of 10 mg/kg, i.p., before subjecting them… (More)
Is this relevant?
1994
1994
OBJECTIVE To examine the antiplatelet effect of a novel pyrazolopyridine derivative (KC-764) in geriatric patients with ischemic… (More)
Is this relevant?
1992
1992
Preclinical pharmacological studies showed that KC-764 was more potent and more selective in inhibiting platelet aggregation than… (More)
Is this relevant?
1992
1992
The effects of KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09-7) on infarct size… (More)
Is this relevant?
1992
1992
The metabolism of KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09-7) in rat, rabbit and… (More)
Is this relevant?
1992
1992
KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo [1,5-a]pyridine CAS 94457-09-7) and its metabolites in serum and urine… (More)
Is this relevant?
1992
1992
Antiplatelet and antithrombotic effects of KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09… (More)
Is this relevant?
1992
1992
The pharmacokinetics of KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09-7) was studied in… (More)
Is this relevant?
1992
1992
KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09-7) was evaluated for the inhibition of… (More)
Is this relevant?